A Phase 2 interventional study of Capecitabine and Fluorouracil in Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma and Stage I Pancreatic Cancer AJCC v6 and v7, sponsored by University of Nebraska. Active, not recruiting at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by University of Nebraska · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.
Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 658th largest by enrollment of the 1,573 interventional ones that give a count, is one of 101 that started in 2017, is one of 488 in phase 2, reaches primary completion later than 23 of the 468 other live ones, and was the 1,032nd registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Anova Innovation Limited · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
IMGT Co., Ltd. · Sites in United States, Korea, Republic of
Ages 18–85
AdventHealth · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,850 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 777 · Phase 2 721 · Phase 3 91 · Phase 4 12
First in 1991; this study’s year is marked. 101 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is close to the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 1,573 interventional studies, 137 across the 230 observational. Of the 1,223 that completed or were terminated, 479 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
576 of 1,850 have an industry lead sponsor. The 10 most frequent:
University of Nebraska is the lead sponsor of 496 studies on the registry; 66 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 53 (64%) have results posted.
University of Nebraska has 9 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
161 of the studies in Pancreatic Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720338Phase 3Case Comprehensive Cancer CenterIs Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | 2026-12-31 |
| NCT03257033Phase 3RenovoRxIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | 2027-06 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT04275557H. Lee Moffitt Cancer Center and Research InstituteUsing Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | 2026-11 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
Add all 161 to your calendar (.ics) → With an account.
Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pancreatic cancer, most commonly adenocarcinoma, is the fourth leading cause of cancer death in the United States. The mainstay of management centers on surgical resection (if resectable) and although low (15% to 20%), resectability rates are associated with dismal survival. An estimated 80% to 85% of the patients recur after surgical resection, leading to a median survival of 20 to 24 months and potentially even less depending on lymph nodal involvement or positive margins. The rationale for utilizing neoadjuvant therapy, commonly fluoropyrimidine-based or gemcitabine based chemotherapy or Chemoradiotherapy (CRT), involves possibly down staging borderline resectable and unresectable patients, potentially making them resectable candidates.
This randomized phase II trial will study how well hypofractionated stereotactic body radiation therapy (SBRT) and fluorouracil or capecitabine with or without zoledronic acid work in treating participants with pancreatic cancer that has spread to nearby tissue or lymph nodes. Hypofractionated stereotactic body radiation therapy is a specialized radiation therapy that sends higher doses of x-rays over a shorter period of time directly to the tumor using smaller doses over several days which may cause less damage to normal tissue. Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Zoledronic acid is used in cancer patients to reduce cancer symptoms and may make tumor cells more sensitive to radiation. Giving hypofractionated stereotactic body radiation therapy and fluorouracil or capecitabine with or without zoledronic acid may work better in treating pancreatic cancer.
Pancreatic cancer, most commonly adenocarcinoma, is the fourth leading cause of cancer death in the United States. The mainstay of management centers on surgical resection (if resectable) and although low (15% to 20%), resectability rates are associated with dismal survival. An estimated 80% to 85% of the patients recur after surgical resection, leading to a median survival of 20 to 24 months and potentially even less depending on lymph nodal involvement or positive margins. The rationale for utilizing neoadjuvant therapy, commonly fluoropyrimidine-based or gemcitabine based chemotherapy or Chemoradiotherapy (CRT), involves possibly down staging borderline resectable and unresectable patients, potentially making them resectable candidates.
This randomized phase II trial will study how well hypofractionated stereotactic body radiation therapy (SBRT) and fluorouracil or capecitabine with or without zoledronic acid work in treating participants with pancreatic cancer that has spread to nearby tissue or lymph nodes. Hypofractionated stereotactic body radiation therapy is a specialized radiation therapy that sends higher doses of x-rays over a shorter period of time directly to the tumor using smaller doses over several days which may cause less damage to normal tissue. Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Zoledronic acid is used in cancer patients to reduce cancer symptoms and may make tumor cells more sensitive to radiation. Giving hypofractionated stereotactic body radiation therapy and fluorouracil or capecitabine with or without zoledronic acid may work better in treating pancreatic cancer.
The primary study objective is to evaluate the efficacy of hypofractionated radiation therapy concurrently with zoledronic acid (Zometa) and fluorouracil or capecitabine. Other study objectives include examining the toxicity of Zometa when used concurrently with hypofractionated radiation therapy, evaluating local failure-free survival and overall survival, determining surgical resection and tumor response rates, measuring Zometa pharmacokinetics, evaluating tumor and organ motion and determining the effect those on the dosimetry, local control and survival. Post-treatment follow-up is for 30 days, then every 3 months for the first year, every 4 months for the second year, and every 6 months thereafter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Participants receive fluorouracil IV over 24 hours on day 1 weekly for 4 weeks or capecitabine by mouth every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Participants then undergo surgery 6-8 weeks after completion of radiation therapy.
Drug: Capecitabine · Drug: Fluorouracil · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study · Radiation: Stereotactic Body Radiation Therapy
Participants receive zoledronic acid IV over a minimum of 15 minutes 1 week prior to radiation therapy. Participants undergo hypofractionated stereotactic body radiation therapy and receive treatment with fluorouracil IV or capecitabine by mouth as in Arm A. Participants then undergo surgery 6-8 weeks after completion of radiation therapy.
Drug: Capecitabine · Drug: Fluorouracil · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study · Radiation: Stereotactic Body Radiation Therapy · Drug: Zoledronic Acid
Given by mouth (PO)
Also known as: Ro 09-1978/000, Xeloda
Given Intravenously (IV)
Also known as: 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757
Correlative studies
Correlative studies
Undergo hypofractionated stereotactic radiotherapy
Also known as: SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
Given IV
Also known as: [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic Acid, CGP 42446, CGP42446A, NDC-Zoledronate, Reclast, ZOL 446, Zometa
Local Control With and Without Zometa at Four Months in Follow-up
Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 4 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.
Time frame: At 4 months in follow-up
Local Control With and Without Zometa at Eight Months in Follow-up
Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 8 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.
Time frame: At 8 months in follow-up
Local Control With and Without Zometa at Twelve Months in Follow-up
Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 12 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.
Time frame: At 12 months in follow-up
Grade 3 and Above Adverse Events With and Without Zoledronic Acid
Grade 3 and above adverse events (AE) will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Time frame: Up to 30 days after treatment
Failure-free Survival With and Without Zometa
Time to any failure (disease progression or recurrence determined by imaging, or death) will be analyzed using Kaplan-Meier method between participants receiving Zometa and those who don't.
Time frame: From date of administration of study drug to the date of any failure, assessed up to 5 years
Overall Survival With and Without Zometa
Time to death will be analyzed using Kaplan-Meier method between participants receiving Zometa and those who don't.
Time frame: From date of administration of study drug to the date of death, assessed up to 5 years
Surgically Complete Resection Rate With and Without Zometa
The number and proportion of participants undergoing complete resection (negative margin) will be determined between participants receiving Zometa and those who don't.
Time frame: Immediately after surgery
Pathologic Response After Resection With and Without Zometa
The pathologic response will be scored from 0-9 by a pathologist, 0 is no response and 9 is complete response between participants receiving Zometa and those who don't.
Time frame: Immediately after surgery
All-Cause Mortality
All anticipated and unanticipated deaths due to any cause
Time frame: From date of administration of study drug to the date of death, assessed up to 10 years
| Milestone | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) |
|---|---|---|
| Started | 23 | 23 |
| Completed | 22 | 20 |
| Not completed | 1 | 3 |
Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 4 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.
| participants | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) |
|---|---|---|
| Local Control With and Without Zometa at Four Months in Follow-up | 22 | 19 |
Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 8 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.
| participants | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) |
|---|---|---|
| Local Control With and Without Zometa at Eight Months in Follow-up | 19 | 18 |
Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 12 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.
| participants | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) |
|---|---|---|
| Local Control With and Without Zometa at Twelve Months in Follow-up | 19 | 17 |
Grade 3 and above adverse events (AE) will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
| participants | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) |
|---|---|---|
| Grade 3 and Above Adverse Events With and Without Zoledronic Acid | 7 | 6 |
Time to any failure (disease progression or recurrence determined by imaging, or death) will be analyzed using Kaplan-Meier method between participants receiving Zometa and those who don't.
| Month | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) |
|---|---|---|
| Failure-free Survival With and Without Zometa | 11 (6.1 to 18.5) | 8 (2.4 to 13.6) |
Time to death will be analyzed using Kaplan-Meier method between participants receiving Zometa and those who don't.
| Month | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) |
|---|---|---|
| Overall Survival With and Without Zometa | 23.9 (11.5 to 30) | 26.1 (9 to 35.3) |
The number and proportion of participants undergoing complete resection (negative margin) will be determined between participants receiving Zometa and those who don't.
| Participants | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) |
|---|---|---|
| Surgically Complete Resection Rate With and Without Zometa | 9 | 8 |
The pathologic response will be scored from 0-9 by a pathologist, 0 is no response and 9 is complete response between participants receiving Zometa and those who don't.
| score | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) |
|---|---|---|
| Pathologic Response After Resection With and Without Zometa | 4 (3 to 7) | 4 (3 to 9) |
All anticipated and unanticipated deaths due to any cause
Results for this outcome have not been posted.
Collected over For each participant, adverse events were collected from the time of informed consent until 30 days after the last study treatment (a combination of RT, chemotherapy, and surgery if applicable). If subjects did not have surgery, it was 30 days post-capecitabine cessation. Adverse event data was collected over 6 years for all participants.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A (Chemotherapy, Radiation Therapy) | 20/22 (90.9%) | 4/22 (18.2%) | 21/22 (95.5%) |
| Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) | 16/20 (80%) | 2/20 (10%) | 19/20 (95%) |
| Event | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) |
|---|---|---|
| FallInjury, poisoning and procedural complications | 0/22 | 1/20 |
| Lung infectionInfections and infestations | 0/22 | 1/20 |
| SomnolenceNervous system disorders | 0/22 | 1/20 |
| Aspartate aminotransferase increasedInvestigations | 1/22 | 0/20 |
| AnorexiaMetabolism and nutrition disorders | 1/22 | 0/20 |
| DehydrationMetabolism and nutrition disorders | 1/22 | 0/20 |
| Hepatobiliary disorders - Other, specifyHepatobiliary disorders | 1/22 | 0/20 |
| Venous InjuryInjury, poisoning and procedural complications | 1/22 | 0/20 |
| Wound complicationInjury, poisoning and procedural complications | 1/22 | 0/20 |
| Event | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) |
|---|---|---|
| DiarrheaGastrointestinal disorders | 2/22 | 9/20 |
| FatigueGeneral disorders | 8/22 | 9/20 |
| NauseaGastrointestinal disorders | 9/22 | 8/20 |
| Aspartate aminotransferase increasedInvestigations | 8/22 | 2/20 |
| Platelet count decreasedInvestigations | 6/22 | 7/20 |
| White blood cell decreasedInvestigations | 6/22 | 7/20 |
| HypocalcemiaMetabolism and nutrition disorders | 5/22 | 6/20 |
| Alanine aminotransferase increasedInvestigations | 6/22 | 1/20 |
| Alkaline phosphatase increasedInvestigations | 6/22 | 4/20 |
| AnemiaBlood and lymphatic system disorders | 6/22 | 5/20 |
| Age, Continuous(year) | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) | Total |
|---|---|---|---|
| Median | 65 (44 to 81) | 64 (48 to 75) | 64.5 (44 to 81) |
| Sex: Female, Male(Participants) | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) | Total |
|---|---|---|---|
| Female | 8 | 8 | 16 |
| Male | 14 | 12 | 26 |
| Race (NIH/OMB)(Participants) | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 21 | 20 | 41 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Arm A (Chemotherapy, Radiation Therapy) | Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) | Total |
|---|---|---|---|
| United States | 22 | 20 | 42 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Dec 2023, 80 months.
Results were first posted in Nov 2026, 2 years 10 months after primary completion.
Of 327 non-industry phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's 80 months is above that.
Counting every sponsor, half of 396 studies reached it within 57 months; a quarter within 35 and three quarters within 80.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Sep 2016 → Mar 2017 and primary completion Dec 2027 → Dec 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zoledronic Acid